Ubiquitin-specific peptidase 10 as a context-dependent deubiquitination hub: integrating stress adaptation, disease progression, and therapeutic opportunities
Experimental Biology and Medicine · 20.11.2026 · 251
DOI: 10.3389/ebm.2026.11322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Biology and Medicine, online erschienen am 20.11.2026. Verfasst von Mohammad Anjum Shaik und 2 weiteren Autor:innen. Die Arbeit nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ubiquitination is a reversible post-translational modification that regulates protein stability, localization, and signaling, while deubiquitinases provide dynamic control over ubiquitin-dependent protein fate. Among these enzymes, ubiquitin-specific peptidase 10 (USP10) has emerged as a highly context-dependent regulator of cellular homeostasis and disease. USP10 influences diverse biological processes, including tumor progression, fibrotic remodeling, mechanotransduction, mitochondrial quality control, metabolic adaptation, and cellular stress responses. Its biological effects are often divergent: in some settings, USP10 supports protective pathways by stabilizing wild-type p53, promoting AMPK-dependent metabolic checkpoints, preserving mitochondrial integrity, and enhancing stress adaptation. In chronic disease contexts it drives pathology by stabilizing oncogenic or profibrotic substrates, including mutant p53, β-catenin, YAP/TAZ, EIF4G1, integrins, and SMAD4. In chronic inflammatory microenvironments, USP10 reinforces disease-promoting signaling through the NEMO/NF-κB and S100A9-SYK-NLRP3 inflammasome axes, increasing inflammatory mediators such as TNF-α, IL-6, CCL2, S100A9, caspase-1/GSDMD, ROS, and profibrotic TGF-β/CTGF pathways. This review synthesizes the dual and context-specific functions of USP10 across cancer, fibrosis, mitochondrial dysfunction, and tissue injury. Rather than functioning as an intrinsically protective or pathogenic enzyme, USP10 acts as a molecular switch whose output is determined by substrate availability, interacting partners, subcellular localization, disease stage, and the surrounding signaling environment. Because accumulating evidence implicates USP10 as a driver of pathology in multiple chronic disease settings, we also examined emerging therapeutic strategies to inhibit USP10 activity, including small-molecule inhibitors, RNA interference approaches, and substrate-selective disruptors. Understanding the context-dependent biology of USP10 will be essential for developing therapeutic strategies that suppress its disease-promoting functions while preserving or enhancing its protective roles.
Zitieren
APA
Shaik, M. A., Banerjee, A., & Bernstein, A. M. (2026). Ubiquitin-specific peptidase 10 as a context-dependent deubiquitination hub: integrating stress adaptation, disease progression, and therapeutic opportunities. Experimental Biology and Medicine, 251. https://doi.org/10.3389/ebm.2026.11322
Vancouver
Shaik MA, Banerjee A, Bernstein AM. Ubiquitin-specific peptidase 10 as a context-dependent deubiquitination hub: integrating stress adaptation, disease progression, and therapeutic opportunities. Experimental Biology and Medicine. 2026;251. doi:10.3389/ebm.2026.11322
BibTeX
@article{Shaik2026,
author = {Shaik, Mohammad Anjum and Banerjee, Arpan and Bernstein, Audrey M.},
title = {Ubiquitin-specific peptidase 10 as a context-dependent deubiquitination hub: integrating stress adaptation, disease progression, and therapeutic opportunities},
journal = {Experimental Biology and Medicine},
year = {2026},
volume = {251},
doi = {10.3389/ebm.2026.11322}
}
EUVIMED